Results for Phase II Clinical Trial of LCL161, a SMAC Mimetic, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (post-PV MF) or Post-Essential Thrombocytosis Myelofibrosis (post-ET MF)

被引：1
|
作者：
Pemmaraju, Naveen
Carter, Bing Z.
Kantarjian, Hagop M.
Cortes, Jorge E.
Kadia, Tapan M.
Garcia-Manero, Guillermo
DiNardo, Courtney D.
Bose, Prithviraj
Pierce, Sherry
Zhou, Lingsha
Estrov, Zeev
Tuttle, Carla Kay
Salinas, Karina
Mak, Po Yee
Verstovsek, Srdan
机构：
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.3105.3105
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3105
引用
收藏
页数：5
相关论文
共 50 条
  • [41] An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
    le Coutre, Philipp D.
    Gisslinger, Heinz
    Zachee, Pierre
    Gupta, Vikas
    Perez, Jose Ricardo
    Schenk, Nora
    Vutukuru, Suresh
    Garcia-Hernandez, Carmen
    Tavares, Renato
    Bocchia, Monica
    Niederwieser, Dietger
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [42] Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
    Shide, Kotaro
    Takenaka, Katsuto
    Kitanaka, Akira
    Numata, Akihiko
    Kameda, Takuro
    Yamauchi, Takuji
    Inagaki, Atsushi
    Mizuno, Shohei
    Takami, Akiyoshi
    Ito, Shinichi
    Hagihara, Masao
    Usuki, Kensuke
    Maekawa, Takaaki
    Sunami, Kazutaka
    Ueda, Yasunori
    Tsutsui, Miyuki
    Ando, Miki
    Komatsu, Norio
    Ozawa, Keiya
    Kurokawa, Mineo
    Arai, Shunya
    Mitani, Kinuko
    Akashi, Koichi
    Shimoda, Kazuya
    ANNALS OF HEMATOLOGY, 2024, 103 (01) : 97 - 103
  • [43] Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval G.
    Pemmaraju, Naveen
    Newberry, Kate J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [44] Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
    Kotaro Shide
    Katsuto Takenaka
    Akira Kitanaka
    Akihiko Numata
    Takuro Kameda
    Takuji Yamauchi
    Atsushi Inagaki
    Shohei Mizuno
    Akiyoshi Takami
    Shinichi Ito
    Masao Hagihara
    Kensuke Usuki
    Takaaki Maekawa
    Kazutaka Sunami
    Yasunori Ueda
    Miyuki Tsutsui
    Miki Ando
    Norio Komatsu
    Keiya Ozawa
    Mineo Kurokawa
    Shunya Arai
    Kinuko Mitani
    Koichi Akashi
    Kazuya Shimoda
    Annals of Hematology, 2024, 103 : 97 - 103
  • [45] Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
    Mora, Barbara
    Rumi, Elisa
    Guglielmelli, Paola
    Barraco, Daniela
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami S.
    Gotlib, Jason R.
    Kiladjian, Jean-Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Cazzola, Mario
    Vannucchi, Alessandro M.
    Giorgino, Toni
    Passamonti, Francesco
    BLOOD, 2018, 132
  • [46] Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Mora, Barbara
    Guglielmelli, Paola
    Kuykendall, Andrew
    Rumi, Elisa
    Maffioli, Margherita
    Palandri, Francesca
    De Stefano, Valerio
    Caramella, Marianna
    Salmoiraghi, Silvia
    Kiladjian, Jean-Jacques
    Gotlib, Jason
    Iurlo, Alessandra
    Cervantes, Francisco
    Ruggeri, Marco
    Silver, Richard T.
    Albano, Francesco
    Benevolo, Giulia
    Ross, David M.
    Della Porta, Matteo G.
    Devos, Timothy
    Rotunno, Giada
    Komrokji, Rami S.
    Casetti, Ilaria C.
    Merli, Michele
    Brociner, Marco
    Caramazza, Domenica
    Auteri, Giuseppe
    Barbui, Tiziano
    Cattaneo, Daniele
    Bertu, Lorenza
    Arcaini, Luca
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    LEUKEMIA, 2022, 36 (10) : 2453 - 2460
  • [47] Results of a randomized study of the JAK inhibitor ruxolitinib (INC424) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia-myelofibrosis (PET-MF)
    Harrison, C. N.
    Kiladjian, J.
    Al-Ali, H. K.
    Gisslinger, H.
    Waltzman, R. J.
    Stalbovskaya, V.
    McQuitty, M.
    Hunter, D. S.
    Levy, R. S.
    Cervantes, F.
    Vannucchi, A. M.
    Barbui, T.
    Barosi, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (18)
  • [48] Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Daver, Naval
    Cortes, Jorge E.
    Estrov, Zeev
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [49] Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Barbara Mora
    Paola Guglielmelli
    Andrew Kuykendall
    Elisa Rumi
    Margherita Maffioli
    Francesca Palandri
    Valerio De Stefano
    Marianna Caramella
    Silvia Salmoiraghi
    Jean-Jacques Kiladjian
    Jason Gotlib
    Alessandra Iurlo
    Francisco Cervantes
    Marco Ruggeri
    Richard T. Silver
    Francesco Albano
    Giulia Benevolo
    David M. Ross
    Matteo G. Della Porta
    Timothy Devos
    Giada Rotunno
    Rami S. Komrokji
    Ilaria C. Casetti
    Michele Merli
    Marco Brociner
    Domenica Caramazza
    Giuseppe Auteri
    Tiziano Barbui
    Daniele Cattaneo
    Lorenza Bertù
    Luca Arcaini
    Alessandro M. Vannucchi
    Francesco Passamonti
    Leukemia, 2022, 36 : 2453 - 2460
  • [50] RUXOLITINIB PLUS PANOBINOSTAT IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA MYELOFIBROSIS OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: A PHASE 1B DOSE-FINDING STUDY
    Vannucchi, A. M.
    Heidel, F. H.
    Ribrag, V.
    Kiladjian, J. J.
    Passamonti, F.
    Hayat, A.
    Conneally, E.
    Kindler, T.
    Martino, B.
    Lipka, D. B.
    Acharyya, S.
    Gopalakrishna, P.
    Loechner, S.
    Mu, S.
    Harrison, C. N.
    HAEMATOLOGICA, 2014, 99 : 129 - 130
12345